Zobrazeno 1 - 10
of 30
pro vyhledávání: '"A. S. Tyulyandina"'
Autor:
A. S. Tyulyandina, E. A. Ulrikh, L. A. Kolomiets, S. E. Krasilnikov, A. G. Kedrova, A. A. Rumyantsev, G. A. Raskin, A. I. Nesterova, M. V. Volkonskiy, O. N. Churuksaeva, A. Yu. Goryainova, V. V. Zhavoronkova, V. N. Dmitriev, S. T. Nazranova, A. V. Shkradyuk, K. S. Volkova, A. I. Arutyunova, S. N. Kunitskaya, L. V. Stepura, T. G. Zolotoreva, E. B. Shakhnovich, E. V. Ponomareva, M. A. Strokova, A. S. Danilova, E. S. Martynova
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 4, Pp 138-146 (2023)
Deficient DNA mismatch repair (dMMR) is a rare molecular disorder found in 20-30 % of endometrial tumors. Laboratory identification of dMMR/microsatellite instability (MSI) has a high diagnostic value, since these impairments are considered as biomar
Externí odkaz:
https://doaj.org/article/dd56d4fb73f4467fa248768ea1bf41c3
Autor:
A. A. Rumyantsev, A. S. Tyulyandina, I. A. Pokataev, E. R. Israelyan, M. Е. Abramov, H. N. Lud, S. A. Tyulyandin
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 77-83 (2022)
Introduction. Olaparib is the only PARP inhibitor approved in Russia for the maintenance therapy for BRCA-positive ovarian cancer after frontline chemotherapy. We conducted a real-world analysis of olaparib efficacy and safety for this indication.Aim
Externí odkaz:
https://doaj.org/article/bfaddd974a224ac8b80f777641cf367f
Autor:
T. A. Bogush, M. B. Stenina, E. A. Bogush, V. T. Zarkua, S. A. Kalyuzhny, I. A. Mamichev, A. S. Tyulyandina, S. A. Tyulyandin
Publikováno v:
Антибиотики и Химиотерапия, Vol 63, Iss 1-2, Pp 24-31 (2020)
Platinum-based drugs are widely used in clinical practice. Their efficacy varies widely among patients, which may be due to a disruption of the expression of ERCC1 - excision repair protein. In the prospective study a strictly quantitative analysis o
Externí odkaz:
https://doaj.org/article/1cf2797fa36d45f4b262fec22b867e8f
Autor:
T. A. Bogush, A. S. Popova, E. A. Dudko, E. A. Bogush, A. S. Tyulyandina, S. A. Tyulyandin, M. I. Davydov
Publikováno v:
Антибиотики и Химиотерапия, Vol 60, Iss 3-4, Pp 42-50 (2020)
The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer. All the variants of the laboratory and clinical ERCC1 assessment in the ovarian cancer tissue (single n
Externí odkaz:
https://doaj.org/article/9388e77230ca4c74a8f6a685601fb976
Autor:
A. A. Rumyantse, A. S. Tyulyandina
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 144-149 (2019)
Ovarian cancer ranks first in the mortality causes pattern of female reproductive cancers in Russia. Treatment of relapsed ovarian cancer remains a significant challenge to practicing oncologists. Introduction of PARP inhibitors in clinical practice
Externí odkaz:
https://doaj.org/article/b7cb9e913efb43a69c53c6968c6db217
Publikováno v:
Опухоли женской репродуктивной системы, Vol 11, Iss 4, Pp 81-86 (2015)
Despite the high initial susceptibility of ovarian cancer (OC) to chemotherapy, the vast majority of patients with Stages III–IV of the disease have its recurrences. Chemotherapy is a main treatment for recurrent OC. In Russia, the rate of platinum
Externí odkaz:
https://doaj.org/article/853eced8219343289f944029fc000821
Autor:
Ye. I. Bateneva, M. G. Filippova, A. S. Tyulyandina, A. A. Meshcheryakov, K. I. Zhordania, A. N. Gritsai, V. V. Kadochnikova, D. D. Abramov, A. A. Ragimov, D. Yu. Trofimov, L. N. Lyubchenko
Publikováno v:
Опухоли женской репродуктивной системы, Vol 0, Iss 4, Pp 51-56 (2015)
Background. The early diagnosis of ovarian cancer (OC) is an important problem in modern gynecological oncology due to significant detection rates for late-stage tumors. Intensive screening of patients from high-risk groups that include OC predisposi
Externí odkaz:
https://doaj.org/article/5f809c4e1f454fe78097631b53e43207
Autor:
A. S. Tyulyandina, V. Yu. Buidenok, K. I. Zhordania, I. V. Panichenko, V. V. Kuznetsov, M. B. Stenina, S. A. Tyulyandin
Publikováno v:
Опухоли женской репродуктивной системы, Vol 0, Iss 3, Pp 99-104 (2014)
Ovarian cancer (OC) is characterized by its late diagnosis, mainly local tumor dissemination within the abdomen and small pelvis, and a relatively high susceptibility to drug therapy . Intraabdominal chemotherapy (CT) allows the higher intraabdominal
Externí odkaz:
https://doaj.org/article/ce4704e24c624cffbaac669ca2f23217
Publikováno v:
Современная онкология, Vol 23, Iss 4, Pp 638-644 (2021)
Aim. To analyze the data available in the modern literature on the role of repeated cytoreduction in the complex treatment of relapses ovarian cancer (OC). Materials and methods. Sources were searched in the following systems Clinicaltrials.gov, P
Externí odkaz:
https://doaj.org/article/08979316763a4b298907f97943e0a34b
Autor:
T. M. Geliashvili, A. S. Krylov, P. I. Bliganov, B. I. Dolgushin, A. I. Pronin, A. S. Tyulyandina, A. V. Parnas, A. D. Ryzhkov, A. V. Pavlova
Publikováno v:
Journal of oncology: diagnostic radiology and radiotherapy. 6:88-96
The expression of prostate-specific membrane antigen (PSMA) on the surface of prostate cancer cells is increased with tumor progression, which is the basis for a theranostic approach in the treatment of these patients. The PSMA ligand, labeled with t